Shares of CapsoVision opened more than 12% below Thursday’s closing level on Friday, with total trading volume reaching 7,782 shares by mid-day. The abrupt move reflects a sudden shift in investor sentiment, marking the stock’s largest single-session opening gap in over six months. Market participants cited a lack of new operational developments as well as the broader healthcare technology sector’s recent volatility as contributing factors.

In the past two months, four equity research firms have updated their outlooks on CapsoVision. Roth Capital lowered its target to $7.00, while Benchmark maintained its speculative buy recommendation. Weiss Ratings reiterated a sell evaluation, and Zacks upgraded the company to a hold stance. Collectively, analysts assign one strong buy, one buy, one hold and one sell, resulting in an average recommendation of Moderate Buy and a consensus target of $6.00.

During the third quarter, CapsoVision reported revenue of $3.54 million and a loss per share that fell $0.03 short of consensus estimates. Despite the earnings miss, New York State Common Retirement Fund initiated a position of 7,114 shares—valued at approximately $34,000—according to the latest 13F filing. This marks the first known institutional investment in CapsoVision this year, signaling some confidence in the company’s long-term diagnostic technology roadmap.

CapsoVision has formally submitted a 510(k) application to the FDA seeking clearance for an AI-assisted software module designed to work with its CapsoCam® Plus system. The module leverages machine-learning algorithms to flag potential gastrointestinal abnormalities automatically, aiming to increase diagnostic accuracy and reduce review times. If cleared, the upgrade would represent the company’s first significant software enhancement and could strengthen its competitive position in the capsule endoscopy market.